Task Force developing European Guidelines for Neuromuscular Blockade Management

NEWS: Uppsala, November 19, 2020. Senzime AB (publ) are pleased to share that ESAIC, The European Society of Anaesthesiology and Intensive Care, has created a Task Force on Neuromuscular Blockade Management Guidelines.

The Task Force has been set-up to provide the rationale and scientific basis for the use of neuromuscular blocking agents in current anaesthesia practice and will also offer a set of recommendations for neuromuscular blockade management. Guidelines-in-development

As part of their work on Patient safety projects, ESAIC has also launched Microlearning Modules on ESAIC Academy, offering among others a webinar on strategies to prevent residual paralysis in the OR.
Webcast on Residual Neuromuscular Paralysis

The speakers from Germany, UK and France key talking points conclude that;

• Optimal surgical conditions can only be maintained and guaranteed by quantitative neuromuscular monitoring
• Correct dosing of reversal agents requires prior knowledge of the degree of residual neuromuscular blockade
• Only quantitative but not qualitative monitoring provides accurate information about the most commonly occurring residual neuromuscular block with a TOFR between 0.4 and 1.0
• Quantitative but not qualitative monitoring significantly reduces the number of patients having unidentified residual neuromuscular block after surgery
• Electromyography (EMG) is the most precise neuromuscular monitoring technique currently available

Senzime’s TetraGraph neuromuscular monitor is an EMG-based unique digital system designed to address the needs of perioperative monitoring of physiologic data in surgical patients receiving general anesthesia and muscle relaxation using neuromuscular blocking drugs (NMBAs). The TetraGraph stimulates a peripheral nerve and measures, analyzes and displays in real-time the muscle function in surgical patients who receive NMBAs as part of their general anesthetic.

For further information, please contact: 

Pia Renaudin, CEO of Senzime AB                                                

Tel: +46 (0)70-813 34 17, email: pia.renaudin@senzime.com 

TO THE EDITORS

About Senzime

Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq
First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se is Certified Adviser for Senzime. www.senzime.com